References for Cell Lines in the Open Distribution List

QuickLinks:   Home » Protocols » Request Cell Lines » Download MTA » Contact
Characterization of Cell Lines
  1. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG: Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer I. 76:375-387, 1986.
  2. Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche TJ, Reynolds C P: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. Cancer Res. 61:6185-6193, 2001.
  3. Reynolds CP, Brodeur GM, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ: Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res. 271:291-306, 1988.
  4. Wada RK, Seeger RC, Brodeur GM, Rayner SA, Tomayko MM, Reynolds CP: N-myc expression in human neuroblastoma cell lines without N-myc gene amplification, Cancer. 72:3346-3354, 1993.
  5. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Research. 58:5396-5405, 1998.
  6. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of Protein Gene Product 9.5 and Tyrosine Hydroxylase in Childhood Small Round Cell Tumors. Clin Cancer Res. 6, 551-558, 2000.
  7. Whiteford CC, Bilke S, Greer BT, Braunschweig TA, Cenacchi N, Wei JS, Smith M, Houghton P, Reynolds CP, Lock R, Gorlick R, Khanna C, Thiele CJ, COG Phase 1 Consortium, Hewitt SM, Khan J: Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 67:32-40, 2007.
  8. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS: Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 38:3751-3757, 1978.
  9. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology (In Press, 2011)


    10. Research Using Neuroblastoma Cell Lines
  10. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemoth Pharm. 45: 1-8, 2000.
  11. Anderson CP, Seeger RC, Satake N, Meek WE, Keshelava N, Bailey HH, Monforte-Munoz HL, Reynolds CP: Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediat Hematol Oncol. 23:500-505, 2001.
  12. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. Cancer Res. 61, 679-686, 2001.
  13. Roberts SS, Mori M, Pattee P, Lapidus J, Mathews R, O'Malley JP, Hsieh YC, Turner MA, Wang Z, Tian Q, Rodland MJ, Reynolds, CP, Seeger RC, Niagalla R: GABAnergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clinical Oncol. 22:4127-4134, 2004.
  14. Yang B, Reynolds CP: Tirapazamine cytotoxicity for neuroblastoma is p53-dependent. Clin Cancer Res. 11:2774-2780, 2005.
  15. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA: The Pediatric Preclinical Testing Program: Description of models and early testing results. Pediatr Blood Cancer. 49:928-940, 2007.
  16. Frgala T, Kalous O, Proffitt RT, Reynolds CP: A novel cytotoxicity assay with a 4 log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther. 6:886-89, 2007.
  17. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. J Natl Cancer I. 99: 1107-19, 2007.
  18. Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP: Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORBTM organized lipid complex in mice. Clin Cancer Res. 13:3079-3086, 2007.
  19. Peng H, Sohara Y, Moats RA, Nelson MD Jr, Groshen SG, Ye W, Reynolds CP, DeClerck YA: The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and ras-mediated tumor cell survival and proliferation. Cancer Res. 67:9346-55, 2007.
  20. Grigoryan RS, Yang B, Keshelava N, Barnhart JR, Reynolds CP: Flow cytometry analysis of single strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. Cytom Part A. 71A:951-960, 2007.
  21. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP: Sodium Thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. Clin Cancer Res. 14:533-540, 2008.


    22. Research Using EFT Cell Lines
  22. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma (ES) and primitive neuroectodermal Tumor (PNET) cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Research 64: 5415-5424, 2004.
  23. Linnoila, R. I., Tsokos, M., Triche, T. J., Marangos, Paul, and Chandra, R. S. (1986). Evidence for Neural Origin and PAS-Positive Variants of the Malignant Small Cell Tumor of Thoracopulmonary Region ("Askin Tumor"). Am J Surg Pathol 10(2): 124-133.
  24. Thiele, Carol J., McKeon, Catherine, Triche, Timothy J., Ross, Robert A., Reynolds, C. Patrick, and Israel, Mark A. (1987). Differential Protoocogene Expression Characterizes Histopathologically Indistinguishable Tumors of the Peripheral Nervous System. J Clin Invest 80: 804-811.
  25. Whang-Peng, J., Triche, T.J., Knutsen, T., Miser, J., Kao-Shan, S., Tsai, S., and Israel, M. A. (1986). Cytogenetic Characterization of Selected Small Round Cell Tumors of Childhood. Cancer Genet Cytogene 21: 185-208.


    26. Research Using Leukemia Cell Lines
  26. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110:205-2066, 2007.
  27. Kang MH, Wan Z, Kang YH, Locke RS, Reynolds CP: Enhanced activity of BH3-mimetic ABT-737 by fenretinide through Mcl-1-inactivation in acute lymphoblastic leukemia cells. J National Cancer Institute 100:580-595, 2008.
  28. Kang MH, Harutyunyan N, Hall CP, Papa RA, Lock RB. (2009) Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma. Br J Haematol 145(3):389-93.


    29. NCI Pediatric Preclinical Testing Program
  29. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA: Initial testing (Stage 1) of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:581-587, 2008
  30. Houghton PJ, Morton CL, Tucker C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Wu J, Smith MA: Stage 1 testing of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:37-45, 2008.
  31. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA: Initial testing of dasatinib by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:1198-1206, 2008.
  32. Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB: Initial testing (Stage 1) of cisplatin by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer (In Press, 2008).
  33. Houghton PJ, Morton CL, Kolb EA, Lock R, Reynolds CP, Maris JM, Keir ST, Billups CA, Tucker C, Smith MA: Initial testing (Stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:709-805, 2008.
  34. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA: Initial testing (Stage 1) of the BH3 Mimetic ABT-263 by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:1181-1189, 2008.
  35. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP,
  36. Maris JM, Keir ST, Billups CA, Smith MA: Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50:1190-1197, 2008.
  37. Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris
  38. JM, Keir ST, Wu J, Houghton PJ. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatric Blood & Cancer 51(1):34-41, 2008.
  39. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatric Blood & Cancer 51:42-8, 2008.
  40. Neal G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ: Molecular characterization of the Pediatric Preclinical Testing panel. Clinical Cancer Research 14:4572-83, 2008.
  41. Petak, I., Douglas, L., Tillman, D.M., Vernes, R., Houghton, J.A. (2000). Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 6, 4119-27. PM:11051265
  42. Hazelton, B.J., Houghton, J.A., Parham, D.M., Douglass, E.C., Torrance, P.M., Holt, H., Houghton, P.J. (1987). Characterization of Cell Lines Derived from Xenografts of Childhood Rhabdomyosarcoma. Cancer Res 47, 4501-7.
  43. Rodriguez-Perales, S., Martinez-Ramirez, A., de Andres, S.A., Valle, L., Urioste, M., Benitez, J., Cigudosa, J.C. (2004). Molecular cytogenetic characterization of rhabdomyosarcoma cell lines. Cancer Genet Cytogenet 148, 35-43. PM:14697639
  44. Leggas, M., Stewart, C.F., Woo, M.H., Fouladi, M., Cheshire, P.J., Peterson, J.K., Friedman, H.S., Billups, C., Houghton, P.J. (2002). Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 8, 3000-7. PM:12231547
  45. Houghton, P.J., Cheshire, P.J., Hallman, J.D., Lutz, L., Friedman, H.S., Danks, M.K., Houghton, J.A. (1995). Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36, 393-403. PM:7634381
  46. Xu, J., Reynolds C.P. (2006). Novel cell lines from pediatric brain tumors showed striking multi-drug resistance. Proc Amer Assoc Cancer Res 47, 4348.
  47. Yee, D., Favoni, R.E., Lebovic, G.S., Lombana, F., Powell, D.R., Reynolds, C.P., Rosen, N. (1990). Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 86, 1806-14. PM:2174908
  48. Thompson, J., Zamboni, W.C., Cheshire, P.J., Lutz, L., Luo, X., Li, Y., Houghton, J.A., Stewart, C.F., Houghton, P.J. (1997). Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3, 423-31. PM:9815701
  49. Sheard, M.A., Kang M.H., Cabral D., Lee J., Castro L., Khankaldyyan V., Wu S.Q., Reynolds C.P. (2007). Bone marrow-level oxygen tension enables enhanced and sustained growth of 3 new pediatric acute lymphoblastic leukemia cell lines. Proc Amer Assoc Cancer Res 48, 1808.
  50. Fischer, P., Nacheva, E., Mason, D.Y., Sherrington, P.D., Hoyle, C., Hayhoe, F.G., Karpas, A. (1988). A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 72, 234-40.
  51. Benjamin, D., Magrath, I.T., Maguire, R., Janus, C., Todd, H.D., Parsons, R.G. (1982). Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type. J Immunol 129, 1336-42. PM:6286763
  52. Klein, G., Giovanella, B., Westman, A., Stehlin, J.S., Mumford, D. (1975). An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5, 319-34. PM:181343
  53. McAllister, R.M., Melnyk, J., Finkelstein, J.Z., Adams, E.C., Jr., Gardner, M.B. (1969). Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 24, 520-6. PM:4241949
  54. Hurwitz, R., Hozier, J., LeBien, T., Minowada, J., Gajl-Peczalska, K., Kubonishi, I., Kersey, J. (1979). Characterization of a leukemic cell line of the pre-B phenotype. Int J Cancer 23, 174-80. PM:83966
  55. Stong, R.C., Korsmeyer, S.J., Parkin, J.L., Arthur, D.C., Kersey, J.H. (1985). Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 65, 21-31. PM:3917311
  56. Minowada, J., Onuma, T., Moore, G.E. (1972). Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 49, 891-5. PM:4567231
  57. Foley, G.E., Lazarus, H., Fabber, S., UZMAN, B.G., Boone, B.A., MCCARTHY, R.E. (1965). Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18, 522-9. PM:14278051
  58. Asou, H., Tashiro, S., Hamamoto, K., Otsuji, A., Kita, K., Kamada, N. (1991). Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77, 2031-6.
 

© Texas Tech University Health Sciences Center (2008-2011)
Shown are confocal images of CHLA-90 (above), and FU-NB-2006 (left).
Confocal images by Felicia Codrea.